Of all the emerging technologies in reproductive medicine, in vitro gametogenesis (IVG) is among the most discussed and the most frequently misunderstood. It appears regularly in headlines describing the future of fertility, sometimes with claims that stretch well beyond what the science currently supports.

This article provides an honest, grounded look at what IVG is, where the research actually stands as of 2026, what barriers remain, and what it could eventually mean for patients who currently have no fertility options, as well as for those going through IVF today.

What Is In Vitro Gametogenesis?

In vitro gametogenesis is the process of generating functional eggs (oocytes) or sperm (spermatozoa) from non-reproductive cells, typically somatic cells such as skin cells or blood cells, outside the body. The term "in vitro" refers to the laboratory setting, and "gametogenesis" refers to the creation of gametes, the reproductive cells.

The theoretical foundation of IVG rests on cellular reprogramming. In 2006, researchers Shinya Yamanaka and colleagues demonstrated that adult somatic cells could be reprogrammed into an induced pluripotent state (iPSCs) capable of differentiating into many cell types. The hypothesis behind IVG is that these iPSCs could then be guided through the complex developmental pathway to produce functional eggs or sperm.

If successfully realized in humans, IVG would represent one of the most significant advances in reproductive medicine in history. It would potentially allow people without functional eggs or sperm to have genetically related children using only a skin biopsy or blood sample. This includes individuals who have gone through premature ovarian insufficiency, cancer treatment, or surgical menopause, as well as individuals assigned male at birth who cannot produce sperm and individuals in same-sex relationships who might wish to have genetically related children.

Where the Research Stands as of 2026

Progress in Animal Models

IVG has been demonstrated in mice. Research teams, most prominently groups in Japan including Mitinori Saitou's laboratory, have successfully produced functional eggs and sperm from mouse iPSCs, fertilized them, and generated live mouse offspring. These experiments represent proof of concept that the biological pathway is achievable, at least in rodent models.

The mouse experiments have also revealed significant complexity. The full IVG pathway involves multiple stages: reprogramming somatic cells to iPSCs, differentiating iPSCs into primordial germ cell-like cells (PGLCs), and then maturing those PGLCs into functional eggs or sperm. In mice, the maturation of PGLCs into functional eggs required a reconstituted ovarian environment in which the PGLCs were co-cultured with supporting cells. The entire process in mice takes months under laboratory conditions.

Human IVG: Early-Stage Research Only

In humans, IVG research has progressed through the earlier stages of this pathway but has not yet achieved what mouse experiments demonstrated. Researchers have successfully generated human primordial germ cell-like cells from iPSCs, but the final maturation step to functional human eggs or sperm capable of fertilization and embryo development remains unaccomplished as of 2026.

The jump from mouse to human is scientifically significant and not straightforward. Human oocyte maturation takes months rather than days, human gametogenesis involves more complex epigenetic reprogramming, and the in vitro conditions required to replicate the ovarian or testicular environment for human germ cell maturation are not yet established.

Ethical and Regulatory Landscape

Even if the science were further advanced, IVG raises substantial ethical and regulatory questions that would need to be addressed before clinical application. The possibility of generating gametes from any somatic cell without the donor's awareness or consent is among the concerns raised. Questions about the epigenetic integrity of lab-derived gametes, long-term health outcomes for offspring, and the regulatory frameworks that should govern IVG development are all active areas of discussion among bioethicists and regulatory bodies.

"IVG is a genuinely exciting area of research, and I think it has real long-term potential for patients who currently have no good options. But as of right now, it is a research technology, not a clinical one. Patients who see headlines about IVG should understand that there is a significant distance between where the science is today and where it would need to be to be available in a clinic."

— Dr. Lyndon Chang, Medical Director at Hanabusa IVF

Who Could IVG Eventually Help?

If IVG is eventually realized as a clinical technology, the populations who could potentially benefit are substantial. Patients with premature ovarian insufficiency who have no remaining eggs could potentially use their own somatic cells to generate eggs for IVF. Cancer survivors who underwent treatment before egg freezing was possible or accessible could potentially access a path to genetic parenthood. Individuals born without reproductive capacity due to chromosomal or developmental conditions might find new options. Same-sex male couples could potentially have genetically related children through IVG-derived eggs, and same-sex female couples could have IVG-derived sperm, though these applications raise distinct ethical considerations.

"The patients I think about most when I read IVG research are the ones sitting across from me today with no eggs, no options, and a profound wish to have a genetically related child. IVG could change that picture someday. I want patients to know that this research exists and is progressing, even as I am honest with them that it is not something they can access right now."

— Dr. Diana LeBlanc, a Fertility Specialist at Hanabusa IVF

What IVG Does Not Change Right Now

For patients going through fertility treatment in 2026, IVG is not a clinical option. The technology does not exist in a form that could be offered in a fertility clinic, and no timeline exists for when it might become available to patients. The gap between proof-of-concept mouse experiments and regulatory-approved human clinical use typically spans decades when reproductive technologies are involved.

For patients currently facing fertility challenges, the best path forward involves the treatments and technologies that are available today. At Hanabusa IVF, that includes a comprehensive range of approaches for complex cases including diminished ovarian reserve, premature ovarian insufficiency, recurrent failed IVF, and patients with few or no remaining eggs, with options such as minimal stimulation IVF, natural cycle IVF, and donor egg programs.

Frequently Asked Questions

Is IVG available at any fertility clinics?

No. As of 2026, IVG is not a clinical technology available to patients at any fertility clinic worldwide. It remains in the laboratory research stage, with proof-of-concept work completed in mice but not yet demonstrated in humans at the level required for clinical use.

Has IVG ever been used in humans?

Not in the sense of producing functional gametes that were used in a clinical pregnancy. Human IVG research has advanced through earlier stages of the gametogenesis pathway, producing cells that resemble early-stage germ cells, but functional human eggs or sperm from somatic cells have not yet been produced in a laboratory setting.

How close is IVG to becoming available?

This is impossible to predict with precision. Scientific timelines for complex technologies are notoriously difficult to estimate, and multiple significant technical barriers remain. Some researchers are cautiously optimistic about progress within the coming decade or two; others emphasize the scale of the biological and regulatory challenges that remain. Patients should not make fertility treatment decisions today based on anticipated IVG availability.

Who would be most helped by IVG if it becomes available?

The populations who would potentially benefit most include individuals with premature ovarian insufficiency, cancer survivors with depleted ovarian reserve, individuals born without reproductive capacity, and same-sex couples who wish to have genetically related children. Many of these groups currently have limited or no options for genetic parenthood.

Should I wait for IVG instead of pursuing IVF now?

No. IVG is not an available treatment and cannot be counted on within a clinically relevant timeframe. If you are currently of reproductive age and facing fertility challenges, pursuing evaluation and treatment now with available technologies is the appropriate course of action. The window for egg freezing or IVF is time-sensitive in a way that IVG's development timeline is not.

Science, Hope, and Honest Expectations

In vitro gametogenesis represents one of the most promising long-term frontiers in reproductive medicine, and at Hanabusa IVF, the team stays current on developments in the field. But hope for what may become possible in the future should not obscure honest counsel about what is available today.

For patients facing complex fertility challenges now, Hanabusa IVF's approach to individualized care, combined with the clinic's expertise in minimal stimulation protocols, complex case management, and its decade-plus of vitrification experience, represents the most meaningful path forward. If you are navigating a diagnosis that leaves you wondering about your options, a consultation at Hanabusa IVF is the right place to start that conversation.

Book your consultation at Hanabusa IVF